NSPR Stock Forecast 2025-2026
Distance to NSPR Price Targets
NSPR Price Momentum
10 Quality Stocks Worth Considering Now
Researching InspireMD (NSPR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NSPR and similar high-potential opportunities.
Latest NSPR Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, NSPR has a bullish consensus with a median price target of $4.75 (ranging from $4.50 to $5.00). Currently trading at $2.60, the median forecast implies a 82.7% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Frank Takkinen at Lake Street, projecting a 92.3% upside. Conversely, the most conservative target is provided by Adam Maeder at Piper Sandler, suggesting a 73.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NSPR Analyst Ratings
NSPR Price Target Range
Latest NSPR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NSPR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 11, 2024 | Lake Street | Frank Takkinen | Buy | Initiates | $5.00 |
| Sep 17, 2024 | Piper Sandler | Adam Maeder | Overweight | Reiterates | $4.50 |
| Nov 2, 2023 | Piper Sandler | Adam Maeder | Overweight | Maintains | $4.50 |
| Jun 12, 2023 | Piper Sandler | Adam Maeder | Overweight | Initiates | $3.00 |
| May 17, 2023 | National Alliance Securities | Ben Haynor | Buy | Maintains | $4.75 |
| Mar 31, 2023 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $5.15 |
| Oct 16, 2020 | Alliance Global Partners | Ben Haynor | Buy | Initiates | $0.70 |
| Mar 11, 2020 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $2.00 |
| Mar 29, 2016 | Rodman & Renshaw | Buy | Maintains | $3.00 |
InspireMD Inc. (NSPR) Competitors
The following stocks are similar to InspireMD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
InspireMD Inc. (NSPR) Financial Data
InspireMD Inc. has a market capitalization of $79.35M with a P/E ratio of -3.4x. The company generates $7.01M in trailing twelve-month revenue with a 21.5% profit margin.
Revenue growth is +10.7% quarter-over-quarter, while maintaining an operating margin of -480.6% and return on equity of -84.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
InspireMD Inc. (NSPR) Business Model
About InspireMD Inc.
Develops innovative embolic prevention medical devices.
InspireMD Inc. generates revenue by selling advanced medical devices, specifically embolic prevention systems and neurovascular devices, that enhance the efficacy and safety of vascular procedures. The company focuses on interventional cardiology and neurovascular markets, targeting severe cardiovascular conditions and distributing its products globally.
Headquartered in Tel Aviv, Israel, InspireMD is committed to advancing healthcare through its proprietary MicroNet™ technology, which aims to reduce risks associated with stenting procedures. The company plays a crucial role in improving patient outcomes and safety in critical medical interventions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
85
CEO
Mr. Marvin L. Slosman
Country
United States
IPO Year
2011
Website
www.inspiremd.comInspireMD Inc. (NSPR) Latest News & Analysis
Latest News
InspireMD, Inc. announced the approval of inducement grants totaling 299,398 shares of restricted stock to 11 new non-executive employees, effective April 1, 2025.
The grant of restricted stock to new employees signals InspireMD's growth and investment in talent, potentially boosting innovation and performance, which can positively impact stock value.
InspireMD, Inc. will present at the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025. The event will cover its CGuard™ Prime carotid stent system. Webcast available for 90 days.
InspireMD's presentation at a key healthcare conference could signal potential growth and investment interest, showcasing their innovative technology in a competitive market.
InspireMD (NASDAQ:NSPR) will hold its Q4 2024 earnings conference call on March 12, 2025, at 8:30 AM ET, featuring CEO Marvin Slosman and CFO Craig Shore.
The earnings call provides insights into InspireMD's financial performance and future outlook, critical for assessing investment potential and market sentiment.
InspireMD, Inc. (Nasdaq: NSPR) reported Q4 and 2024 results, highlighting FDA engagement for CGuard™ Prime approval, enrollment in pivotal study, and record revenues of $1.95M. Headquarters moved to Miami.
InspireMD's advancements in FDA approval and market performance indicate potential growth, impacting stock value and investor confidence as they prepare for a U.S. launch of their carotid stent system.
InspireMD, Inc. (NSPR) reported a quarterly loss of $0.19 per share, better than the estimated loss of $0.20, but worse than a loss of $0.16 per share a year earlier.
InspireMD's smaller-than-expected loss indicates potential operational improvements, which may boost investor confidence and influence stock performance. Year-over-year comparison shows worsening performance.
InspireMD, Inc. (Nasdaq: NSPR) will release its Q4 and full-year 2024 financial results on March 12, 2025, and will host a conference call at 8:30 a.m. the same day.
InspireMD's upcoming financial results and conference call could influence stock prices, indicating company performance and future prospects in the medical device market.
Frequently Asked Questions About NSPR Stock
What is InspireMD Inc.'s (NSPR) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, InspireMD Inc. (NSPR) has a median price target of $4.75. The highest price target is $5.00 and the lowest is $4.50.
Is NSPR stock a good investment in 2025?
According to current analyst ratings, NSPR has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NSPR stock?
Wall Street analysts predict NSPR stock could reach $4.75 in the next 12 months. This represents a 82.7% increase from the current price of $2.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is InspireMD Inc.'s business model?
InspireMD Inc. generates revenue by selling advanced medical devices, specifically embolic prevention systems and neurovascular devices, that enhance the efficacy and safety of vascular procedures. The company focuses on interventional cardiology and neurovascular markets, targeting severe cardiovascular conditions and distributing its products globally.
What is the highest forecasted price for NSPR InspireMD Inc.?
The highest price target for NSPR is $5.00 from Frank Takkinen at Lake Street, which represents a 92.3% increase from the current price of $2.60.
What is the lowest forecasted price for NSPR InspireMD Inc.?
The lowest price target for NSPR is $4.50 from Adam Maeder at Piper Sandler, which represents a 73.1% increase from the current price of $2.60.
What is the overall NSPR consensus from analysts for InspireMD Inc.?
The overall analyst consensus for NSPR is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.75.
How accurate are NSPR stock price projections?
Stock price projections, including those for InspireMD Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.